EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting Akt Signaling Pathway in Cancer: Molecular Mechanisms and Advances in Therapeutic Interventions

Premila D Leiphrakpam, Rishi Batra, Laura Tenner, Chandrakanth Are

Frontiers in Bioscience-Landmark · 11.11.2025 · 30 (11)

DOI: 10.31083/fbl39100 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Bioscience-Landmark, online erschienen am 11.11.2025. Verfasst von Premila D Leiphrakpam und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA. Hauptthemen laut MEDLINE: Neoplasms, Proto-Oncogene Proteins c-akt, Signal Transduction. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 128 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Akt/PKB (protein kinase B) is a major transducer of the phosphoinositide 3-kinase (PI3K) signaling axis, regulating key cellular processes such as growth, proliferation, apoptosis, survival, and migration in both normal and cancer cells. In normal cells, oncoproteins and tumor suppressor proteins within the Akt pathway exist in equilibrium. However, this equilibrium is disrupted in cancer cells due to activating mutations in oncoproteins and inactivating mutations in tumor suppressor proteins. This dysregulation drives tumor growth and progression, making the Akt pathway an attractive target for cancer therapies. A deeper understanding of the molecular mechanisms of the Akt signaling pathway is crucial for developing novel therapeutic agents targeting Akt and its downstream effectors for cancer treatment. This review discusses the role of Akt in cancer, current Akt-targeted agents, their limitations, and future trends.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsProto-Oncogene Proteins c-aktSignal TransductionHumansAntineoplastic AgentsAnimalsMolecular Targeted TherapyProtein Kinase InhibitorsPhosphatidylinositol 3-Kinases

Stichwörter der Autor:innen

AktPI3Kcancercell survivalinhibitorstargeted therapy

Substanzen

Proto-Oncogene Proteins c-aktAntineoplastic AgentsProtein Kinase InhibitorsPhosphatidylinositol 3-Kinases

Autor:innen und Institutionen

  • College of Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA.
  • Division of Surgical Oncology, Department of Surgery, College of Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA.
  • Division of Colon & Rectal Surgery, Department of Surgery, College of Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA.
  • Division of Oncology & Hematology, Department of Internal Medicine, College of Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA.

Zitieren

APA

Leiphrakpam, P. D., Batra, R., Tenner, L., & Are, C. (2025). Targeting Akt Signaling Pathway in Cancer: Molecular Mechanisms and Advances in Therapeutic Interventions. Frontiers in Bioscience-Landmark, 30(11). https://doi.org/10.31083/fbl39100

Vancouver

Leiphrakpam PD, Batra R, Tenner L, Are C. Targeting Akt Signaling Pathway in Cancer: Molecular Mechanisms and Advances in Therapeutic Interventions. Frontiers in Bioscience-Landmark. 2025;30(11). doi:10.31083/fbl39100

BibTeX
@article{Leiphrakpam2025,
  author = {Leiphrakpam, Premila D and Batra, Rishi and Tenner, Laura and Are, Chandrakanth},
  title = {Targeting Akt Signaling Pathway in Cancer: Molecular Mechanisms and Advances in Therapeutic Interventions},
  journal = {Frontiers in Bioscience-Landmark},
  year = {2025},
  volume = {30},
  number = {11},
  doi = {10.31083/fbl39100}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche